Lumisight (pegulicianine)
Research Synopsis
- Lumisight (pegulicianine) is a novel imaging agent used in fluorescence-guided surgical techniques for improving outcomes in breast-conserving surgery.
- A study published in JAMA Surgery (2022) involving 234 women demonstrated that pegulicianine helped in real-time identification of residual cancer, aiming to reduce the need for additional surgeries.
- Intraoperative margin assessment with pegulicianine showcased minimal adverse reactions among participants during the trial, indicating a favorable safety profile.
- A recent multicenter trial in NEJM Evidence (2023) highlighted the effectiveness of pegulicianine combined with an optical device to enhance surgical precision by targeting lumpectomy margins.
- The trials aim to address challenges like incomplete tumor removal, which can lead to local recurrence and necessitate further surgeries.
- Despite some success in avoiding additional surgeries, the overall sensitivity of pegulicianine fluorescence-guided surgery was lower than expected.
- However, it still met specificity benchmarks, confirming its relevance in identifying cancerous tissue.
- Researchers continue to explore the potential of pegulicianine to improve surgical outcomes and reduce recurrence rates in breast cancer treatment.
- As of October 2023, research indicates a positive sentiment around pegulicianine's role in enhancing surgical techniques, although additional refinement and studies may be necessary to fully realize its potential.
- Further investigations are encouraged to optimize the use of pegulicianine to overcome its current limitations in sensitivity.
Lumisight (pegulicianine)
Lumisight table: an interactive view-dependent tabletop display.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Clinical Impact of Intraoperative Margin Assessment in Breast-Conserving Surgery With a Novel Pegulicianine Fluorescence-Guided System: A Nonrandomized Controlled Trial.
London, UK
2 hours ago
1 Received
- The study investigates a new imaging technique called pegulicianine fluorescence-guided system (pFGS) to improve outcomes in breast-conserving surgery (BCS) by identifying remaining cancer in real-time.
- Conducted across 16 centers, 234 eligible women participated, receiving pegulicianine before surgery, with a focus on safety and efficacy data during a follow-up period.
- Results showed that the majority of participants completed the trial with minimal adverse reactions, aiming to reduce the need for further surgery and improve surgical precision.
$100 - $150
Hourly Rate
Something to Dye For: Toward Better Breast Lumpectomy Margins.
London, UK
2 hours ago
1 Received
- The advancement of fluorescence imaging in cancer surgery allows for enhanced surgical precision with intraoperative devices.
- A multicenter trial by Smith et al. tested intravenous pegulicianine combined with an optical device to identify cancerous lumpectomy margins during surgery.
- This method aims to reduce the need for additional surgeries by immediately excising cancerous tissue identified during the operation.
$100 - $150
Hourly Rate
Intraoperative Fluorescence Guidance for Breast Cancer Lumpectomy Surgery.
London, UK
2 hours ago
1 Received
- Lumpectomy and mastectomy have similar survival rates for breast cancer patients, but incomplete tumor removal indicated by positive lumpectomy margins can lead to local recurrence and increased mortality, often requiring a second surgery.
- A clinical trial was conducted to determine the effectiveness of pegulicianine fluorescence-guided surgery (pFGS) in identifying cancerous margins during lumpectomy for various breast cancer stages, where patients were randomly assigned to pFGS or control groups to evaluate margin status.
- Results showed that pFGS successfully identified residual tumors in some cases, avoiding second surgeries for some patients with positive margins; however, the overall sensitivity of pFGS was lower than hoped despite meeting specificity and successfully removing some remaining cancer.
$100 - $150
Hourly Rate